Circulating microRNAs as potential new biomarkers for prostate cancer

Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide potential new biomarkers for prostate cancer...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2013-05, Vol.108 (10), p.1925-1930
Main Authors: Sita-Lumsden, A, Dart, D A, Waxman, J, Bevan, C L
Format: Article
Language:English
Subjects:
631/337/384/331
631/67/1857
631/67/589/466
692/700/1750
Algorithms
Bioindicators
Biological and medical sciences
Biological Transport - physiology
Biomarkers
Biomarkers, Tumor - blood
Biomedical and Life Sciences
Biomedicine
Biopsy
Cancer Research
Cancer therapies
Drug Resistance
Epidemiology
Humans
Male
Medical prognosis
Medical research
Medical sciences
MicroRNAs
MicroRNAs - blood
mini-review
MiniReview
Molecular Medicine
Molecular Targeted Therapy
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Nephrology. Urinary tract diseases
Oncology
Ovaries
Patients
Prognosis
Prostate cancer
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - genetics
Prostatic Neoplasms - therapy
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide potential new biomarkers for prostate cancer, the most common cause of cancer in UK men. Current diagnostic tests for prostate cancer have low specificity and poor sensitivity. Further, although many prostate cancers are so slow growing as not to pose a major risk to health, there is currently no test to distinguish between these and cancers that will become aggressive and life threatening. Circulating miRNAs are highly stable and are both detectable and quantifiable in a range of accessible bio fluids, thus have the potential to be useful diagnostic, prognostic and predictive biomarkers. This review aims to summarise the current understanding of circulating miRNAs in prostate cancer patients and their potential role as biomarkers.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2013.192